Monoclonal Antibodies Ka'idoji don Ciwon daji

Manufar Targetar cutar sankarar bargo da Lymphoma

Tsarinka na rigakafi yana samar da kwayoyin cutar a sakamakon amsawar '' tags '' '' ''. Wadannan kalmomi da ake kira antibodies ana kiran antigens. Tsarin na rigakafi na iya gane antigens akan kwayoyin cuta da kuma antigens akan kwayoyin jikinsu - lokacin da suka zama kamuwa da cuta ko cutar, misali. Lokacin da wani mutum ya yi kama da antigen, zai iya daukar nauyin tsarin rigakafi don halakar da manufa.

Anyi amfani da kwayoyin monoclonal, ko mAbs, don magance cututtuka daban-daban, ciki har da wasu irin ciwon daji. Akwai sha'awar sha'awa game da mAbs da kuma yiwuwar su kara yawan ciwon daji . Amfani tare da chemotherapy, wasu mAbs suna da tsawon lokacin rayuwa.

Menene Ma'anar Monoclonal Ma'anar?

Monoclonal na nufin 'kawai clone', wanda ke buƙatar ƙarin bayani. Yawancin lokaci, lokacin da tsarin lafiyarka ya ga mai haɗari, zai samar da nau'in kwayoyi masu kyau - kowane irin nau'in, don ƙaddamar da nau'ikan nau'ikan nau'i da maƙalai akan farfaɗo. Wadannan cututtuka sune kwayoyin cutar polyclonal, ma'ana cewa '' clones 'daban-daban ko iyalai na kwayoyin jikinsu sun hada kokarin da za su yi duk wani ɓangaren magunguna don kai hari ga mai haɗari.

Masana kimiyya sun kasance sun fi dacewa wajen magance ciwon daji, kuma suna yin amfani da gungun nau'o'i daban-daban , ƙuƙwalwa da kuma kalmomi a kan kwayar cutar kanjamau na iya zama mai kyau, amma ba dole ba ne.

Alal misali, idan idan ɗaya daga cikin wadanda aka yi niyya a kan kwayar cutar kanjamau ya kasance yana da yawa a duk al'ada, kwayoyin lafiya kuma?

Magungunan monoclonal, to, su ne maganin rigakafi da aka yi a cikin wani Labari ta hanyar masana kimiyya - kwayoyin cutar da aka tsara don ƙaddamar da ƙwayoyin cuta guda ɗaya, musamman da aka sani - sau da yawa sunadaran a kan ciwon daji.

Misalan hanyoyin maganin mAb don maganin cututtuka na jini sun hada da Rituxan (rituximab), da Gazyva (obinutuzumab) , dukansu biyu sune magungunan CD20. CD20 yana daya daga mahimmanci daban-daban a kan farfadogin B, ko B-lymphocytes, wanda ya haifar da yawan lymphomas.

Ta yaya Monoclonal Antibodies Work?

MAbs za su iya aiki a matsayin tashoshi, ko sigina, don faɗakar da shirin rigakafi:

Za a iya tsara maɓannai don sadaukar da damuwa mai guba idan sun sami manufa:

Ta Yaya Aka Ba Kwayoyi Daga Monoclonal?

An bayar da kwayoyin cutar ta jiki a cikin intravenously, ta hanyar magani, a asibiti ko a asibitin. Wasu magunguna za a iya ba da su kafin su rage yawan yiwuwar halayen da kuma illa masu tasiri.

Mafi mahimmanci, idan aka yi amfani dashi a matsayin maganin cutar sankarar bargo ko lymphoma, ana ba da magunguna guda daya a hade tare da maganin gargajiya na gargajiya. Yawan lokuttan da aka tsara, ko hawan keke, da aka ba da mAb a cikin gwajin ya dogara da wasu nau'o'i daban-daban, ciki har da wasu dalilai da zasu iya ƙayyade a gare ku da kuma rashin lafiya.

Hanyoyi na gefen Monoclonal Antibodies

Duk da yake cututtukan cututtuka na maganin mAb ba su da kama da chemotherapy, suna faruwa.

Wasu mawuyacin sakamako na iya zama kama da rashin lafiyan-irin halayen. Hanyoyi masu tasiri na iya dogara ne akan nau'in mAb da aka ba, mutum mai haƙuri da yanayin kiwon lafiyarta, da irin rashin tausayi da sauran dalilai. Wasu halayen sakamako na mAb na al'ada sun haɗa da haka:

Updated TI.

Sources:

> Abernathy, E. (1997). Biotherapy. A cikin Varricchio, C. (Ed.) Littafin Littafin Cutar Cancer na Nurses -7th ed. (pp.379-390). Atlanta, Jojiya: Cibiyar Kwayoyin Ciwon daji ta Amirka.

> Battiato, L. da Wheeler, V. (2000). Biotherapy. A Yarbro, C., Frogge, M., Goodman, M., et al (Eds.) Ka'idojin Nursing Cancer da Practice-5th ed. (shafi na 1244-1269). London, Ingila: Jones da kuma Bartlett Publishers International

> Yarocci, Thomas. Gazyva na Lymphoma na Non-Hodgkin

> Yarocci, Thomas. Ciwon daji na jini da kuma ciwon jini.

> NCCN. Masu haƙuri da masu ba da taimako. Magunguna da aka ƙayyade.

> RS Cvetkovic da CM Perry "Rituximab: Binciken Amfani da shi a Lymphoma da Lychocytic na Lamijina." Drugs 2006 66 (6): 791-820.